Edition:
India

AbbVie Believes It Is Unlikely There Will Be A Botox Biosimilar For A Long Time - Conf. Call


Tuesday, 25 Jun 2019 

June 25 (Reuters) - AbbVie Inc ::ABBVIE INC EXECUTIVE SAYS ASSETS OF THE QUALITY OF ALLERGAN ARE NOT ALWAYS AVAILABLE AND NOT CERTAINLY AT THIS VALUE: CONF. CALL.ABBVIE CEO SAYS BELIEVES IT IS HIGHLY UNLIKELY THERE WILL BE A BOTOX BIOSIMILAR FOR A LONG TIME.ABBVIE CEO SAYS FEELS COMFORTABLE WITH RISK RELATED TO ALLERGAN'S OPIOID EXPOSURE.ABBVIE CEO SAYS ALLERGAN BREAKUP FEE IS 1% FOR ALLERGAN, 2% FOR ABBVIE : CONF. CALL.ABBVIE EXECUTIVE SAYS NOT BUILDING IN A LARGE CONTRIBUTION FROM ALLERGAN'S PIPELINE INTO ITS PROJECTIONS.